Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) VP Russell Kevin Klass acquired 299,993 shares of the business's stock in a transaction that occurred on Wednesday, June 12th. The shares were acquired at an average cost of $0.16 per share, with a total value of $47,998.88. Following the completion of the transaction, the vice president now directly owns 2,000,050 shares in the company, valued at approximately $320,008. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Zomedica Price Performance
Zomedica stock remained flat at $0.16 during midday trading on Thursday. The company had a trading volume of 2,905,964 shares, compared to its average volume of 5,633,809. Zomedica Corp. has a 12 month low of $0.12 and a 12 month high of $0.25. The stock has a market cap of $152.48 million, a PE ratio of -3.91 and a beta of 0.88.
Zomedica (NYSEAMERICAN:ZOM - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $6.26 million during the quarter. Zomedica had a negative net margin of 143.67% and a negative return on equity of 8.62%.
Institutional Investors Weigh In On Zomedica
Institutional investors have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC acquired a new position in shares of Zomedica in the fourth quarter valued at approximately $43,000. Frazier Financial Advisors LLC acquired a new position in shares of Zomedica in the fourth quarter valued at approximately $50,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Zomedica by 41.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 948,300 shares of the company's stock valued at $139,000 after purchasing an additional 276,100 shares during the period. Finally, Virtu Financial LLC increased its holdings in shares of Zomedica by 1,585.0% in the first quarter. Virtu Financial LLC now owns 168,773 shares of the company's stock valued at $25,000 after purchasing an additional 158,757 shares during the period. Hedge funds and other institutional investors own 8.95% of the company's stock.
Zomedica Company Profile
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.
While Zomedica currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
